Johnson & Johnson seek US approval of world’s first single-dose COVID-19 vaccine.
On February 4, Johnson & Johnson asked US regulators to approve the licensing of the world’s first single-dose COVID-19 vaccine.
The US Food and Drug Administration is asking its independent advisers to publicly analyze all data and parameters related to a single dose of COVID-19 vaccine, similar to the one for vaccines of other pharmaceutical companies, before deciding whether to “green light” to license the third vaccine in the US or not. The jury will meet on February 26.
According to Johnson & Johnson, the single- dose COVID-19 vaccine is a more appropriate option that could boost a scarce vaccine supply.
According to initial trial results from a study of more than 44,000 people in the US, Latin America and South Africa, the COVID-19 vaccine using a single dose of Johnson & Johnson is about 66% effective in preventing COVID 19 from moderate to severe.
Specifically, the single-dose vaccine worked better in the US with 72% of the efficacy in patients with moderate to severe COVID-19, 66% in Latin America and 57% in South Africa, where one type of variant came from.
Preliminary results from a large-scale international study show that the Johnson & Johnson COVID-19 vaccine provides strong protection against moderate to severe COVID-19.
As the world is racing to embrace a rapidly spreading strain of the virus, many scientists are looking for real-life evidence of how vaccines work and advocating for Johnson’s single-dose vaccine selection.